Such an approach, in combination with immune checkpoint blockade, could harness colorectal cancer cells as surrogate APCs and generate cancer cells as direct targets for CD4+ T cells and improve the effectiveness of immunotherapy in tumors such as pMMR colorectal cancer. Here, CD4 is linked to colorectal cancer.